Skip to main content
    S

    Sophia Genetics SA (SOPH)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $7.06
    -0.03 (-0.42%)

    Market Cap: $601.00M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(16/21)
    Avg Surprise
    +5.39%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.19-5.3%
    60d ago$-0.19-5.3%
    30d ago$-0.19-5.3%
    7d ago$-0.19-5.3%
    Current$-0.20
    Revenue Consensus
    $24M
    Range$23M - $25M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.19
    Range$-0.19 - $-0.19
    1 analysts
    Revenue Consensus
    $29M
    Range$29M - $30M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.19---
    Sep 26EST
    		-$-0.20---
    Jun 26
    Reported Aug 4
    		$-0.26$-0.15-73.33%Miss-4.0%
    Mar 26
    Reported May 5
    		$-0.19$-0.24+20.83%Beat-5.6%
    Dec 25
    Reported Mar 3
    		$-0.17$-0.22+22.41%Beat-42.4%
    Sep 25
    Reported Nov 4
    		$-0.20$-0.20+0.00%Beat+4.8%
    Jun 25
    Reported Aug 5
    		$-0.25$-0.17-47.06%Miss-66.7%
    Mar 25
    Reported May 6
    		$-0.18$-0.19+5.26%Beat-28.6%
    Dec 24
    Reported Mar 4
    		$-0.12$-0.15+20.07%Beat+67.6%
    Sep 24
    Reported Nov 5
    		$-0.21$-0.18-16.67%Miss-50.0%
    Jun 24
    Reported Aug 6
    		$-0.15$-0.20+25.00%Beat+40.0%
    Mar 24
    Reported May 7
    		$-0.14$-0.21+33.33%Beat+46.2%
    Dec 23
    Reported Mar 5
    		$-0.37$-0.27-37.04%Miss-68.2%
    Sep 23
    Reported Nov 7
    		$-0.14$-0.24+41.67%Beat+61.1%
    Jun 23
    Reported Aug 8
    		$-0.25$-0.26+3.85%Beat+19.4%
    Mar 23
    Reported May 9
    		$-0.26$-0.28+7.14%Beat+23.5%
    Dec 22
    Reported Mar 7
    		$-0.22$-0.36+38.89%Beat+21.4%
    Sep 22
    Reported Nov 8
    		$-0.36$-0.36+0.00%Beat-20.0%
    Jun 22
    Reported Aug 9
    		$-0.31$-0.39+20.51%Beat+0.0%
    Mar 22
    Reported May 10
    		$-0.34$-0.30-13.33%Miss-30.8%
    Dec 21
    Reported Mar 15
    		$-0.28$-0.36+22.22%Beat-6.1%
    Sep 21
    Reported Nov 10
    		$-0.30$-0.37+18.92%Beat-9.2%
    Jun 21
    Reported Jul 23
    		$-0.31$-0.39+20.51%Beat-
    Mar 21
    Reported Jun 2
    		$-0.26$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-0.26$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-0.27$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-8.60EV/EBITDAN/A
    Price/FCF-11.42xFCF Yield-8.75%
    Profitability
    Profit Margin-93.90%Operating Margin-86.00%
    ROE-101.20%ROIC-55.51%
    Financial Health
    Debt/Equity0.61xInterest Coverage-11.22x
    Current Ratio2.69xQuick Ratio2.55x
    Trading Statistics
    Beta0.95Avg Volume696.41K
    52-Week High$8.9852-Week Low$3.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.49
    SMA 20$7.89
    SMA 50$7.93
    SMA 200$5.81
    EMA 10$7.44
    EMA 20$7.68
    EMA 50$7.56
    EMA 200$6.10

    MACD

    Line: -0.21Signal: -0.08Hist: -0.14

    ADX

    ADX: 23.9+DI: 14.8-DI: 19.3

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down84.0
    PSAR$7.91

    Bollinger Bands

    Upper Band$8.93
    Lower Band$6.85
    %B Position2629%(Upper)
    Band Width0.10

    RSI (14-Day)

    Neutral
    36.8

    Momentum Oscillators

    Stoch %K15.0
    Stoch %D20.3
    Williams %R-88.4
    ROC (10d)-15.8%
    Momentum-1.32
    CCI (20d)-124.7
    MFI (14d)40.7

    Volatility Measures

    ATR (14d)$0.46(6.6%)
    StdDev (20d)0.52
    Hist Vol54.6%(High)

    Volume Flow

    VWAP$7.09
    OBV17.2M
    AD Line8.2M
    CMF (20d)-0.111

    Volume Metrics

    Avg Vol (20d)598.4K
    Vol Ratio0.6x
    VWMA (20d)$7.97

    Pivot Points

    R3$7.54
    R2$7.43
    R1$7.26
    Pivot Point$7.16
    S1$6.99
    S2$6.88
    S3$6.71

    Advanced Oscillators

    TSI-14.34
    Ultimate Osc35.9
    KST-59.32

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$23.31M$21.69M$21.71M$19.46M$18.32M$17.78M$17.73M$15.85M$15.81M$15.78M$17.05M$16.30M
    Cost of Revenue$8.25M$6.94M$7.01M$6.55M$6.05M$5.57M$5.63M$5.20M$5.03M$5.37M$5.15M$5.03M
    Gross Profit$15.06M$14.75M$14.69M$12.91M$12.27M$12.21M$12.10M$10.65M$10.78M$10.40M$11.90M$11.27M
    Operating Expenses$35.11M$32.03M$32.74M$30.77M$30.83M$28.24M$29.55M$26.02M$25.78M$29.16M$30.85M$27.82M
    R&D$8.73M$11.06M$8.54M$9.40M$8.49M$9.12M$9.14M$7.87M$7.96M$9.39M$9.76M$8.98M
    SG&A$15.20M$13.76M$22.04M$13.89M$12.30M$11.60M$12.66M$10.88M$10.58M$12.82M$13.27M$12.75M
    Operating Income$-20,053,000$-17,283,000$-18,049,000$-17,862,000$-18,558,000$-16,036,000$-17,444,000$-15,363,000$-15,005,000$-18,756,000$-18,947,000$-16,544,000
    Interest Income$231,000$289,000$381,000$622,000$419,000$450,000$1.89M$267,000$450,000$758,000$0$0
    Interest Expense$1.62M$1.67M$1.67M$1.66M$559,000$659,000$1.91M$2.94M$501,000$143,000$5.11M$0
    Income Before Tax$-22,278,000$-19,069,000$-19,574,000$-19,379,000$-21,652,000$-16,882,000$-14,542,000$-18,308,000$-15,032,000$-13,388,000$-24,053,000$-13,525,000
    Income Tax Expense$78,000$253,000$-395,000$642,000$762,000$503,000$616,000$130,000$161,000$316,000$8,000$299,000
    Net Income$-22,356,000$-19,322,000$-19,179,000$-20,021,000$-22,414,000$-17,385,000$-15,158,000$-18,438,000$-15,193,000$-13,704,000$-24,061,000$-13,824,000
    EBITDA$-17,751,000$-14,651,000$-15,463,000$-15,914,000$-18,723,000$-13,926,000$-7,946,000$-16,095,000$-12,494,000$-11,186,000$-20,047,000$-11,324,000
    EBIT$-20,658,000$-17,402,000$-17,901,000$-18,338,000$-21,093,000$-16,223,000$-10,233,000$-18,308,000$-14,531,000$-13,245,000$-22,028,000$-13,525,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SOPH

    Government Contracts

    Gov Obligations (TTM)
    $1.12M
    Gov Obligations / Revenue
    1.4%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    1.8 mo

    Top agency: Department of Defense at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    HT940825CE005Department of DefenseDefense Health Agency$1.12MSep 30, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $28,720.00 in Stock

    SOPHiA GENETICS insider Zhenyu Xu sold 4,000 shares of the company's stock for $28,720 on October 13, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. This sale decreased Xu's ownership by 0.73%...

    MarketBeat•10/14/26•Somewhat-Bearish

    Jurgi Camblong Executes Sale of 8,500 SOPHiA GENETICS Shares on October 12 Under Rule 10b5-1 Plan

    Jurgi Camblong, Executive Chairman and Director of SOPHiA GENETICS SA (NASDAQ:SOPH), sold 8,500 ordinary shares on October 12...

    Kalkine Media•10/14/26•Neutral

    SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 8,500 Shares of Stock

    SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong sold 8,500 shares of the company's stock for $61,710 under a pre-arranged Rule 10b5-1 trading plan. This transaction, along with other recent sales...

    MarketBeat•10/14/26•Somewhat-Bearish

    Form 4 SOPHiA GENETICS SA: Zhenyu Xu (Chief Scientific Officer) For: 13 October

    This article reports a Form 4 filing for SOPHiA GENETICS SA, indicating an insider transaction by Zhenyu Xu, the Chief Scientific Officer...

    Investing.com India•10/14/26•Neutral

    Form 144 SOPHIA GENETICS SA For: 12 October By Investing.com

    This article announces the filing of Form 144 for SOPHIA GENETICS SA on October 12. It is a brief, standard notification provided by Investing.com...

    Investing.com Nigeria•10/12/26•Neutral

    SOPH Valuation and Fair Value

    P/E
    -8.6x
    P/FCF
    -11.4x
    P/B
    6.3x
    See GNG's fair value

    SOPH Profitability: Margins, ROIC and FCF

    Gross margin
    66.6%
    Operating margin
    -86.0%
    Net margin
    -93.9%
    ROIC
    -55.5%
    ROE
    -101.2%
    FCF margin
    -53.0%
    FCF yield
    -8.8%

    SOPH Competitors

    CompanyTicker
    ProKidney Corp.PROK
    Phathom Pharmaceuticals IncPHAT
    Zevra Therapeutics Inc.ZVRA
    Olema Pharmaceuticals IncOLMA
    SurModics IncSRDX
    Ironwood Pharmaceuticals IncIRWD
    Pacific Biosciences of CaliforniaPACB
    Weave Communications IncWEAV

    Sector: Healthcare

    SOPH Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SOPH Bull Case vs Bear Case

    Bull case

    • SOPH grew quarterly revenue 27.2% year over year.
    • 100.0% of SOPH's analyst ratings are Buy or Strong Buy.

    Bear case

    • SOPH has a -93.9% net profit margin.

    SOPH Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -8.6%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    Frequently Asked Questions About SOPH

    Does SOPH pay dividends?

    Sophia Genetics SA (SOPH) does not currently pay a regular dividend.

    What is SOPH's market cap?

    Sophia Genetics SA (SOPH) has a market capitalization of $601.00M with a current stock price of $7.06.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In